Oral Abstract Session
Cardiovascular-Kidney-Metabolic Syndrome: Trials, Mechanisms, and Population Health
October 22, 2026 | 04:30 PM - 06:00 PM
Location: Room 205, Convention Center
Session Description
Oral Abstract Session
Learning Pathway(s)
- Cardiovascular-Kidney-Metabolic (CKM) Health
Moderators
Presentations
Enlicitide, an Oral PCSK9 Inhibitor, for Lipid Lowering: Pooled Analysis of the Phase 3 CORALreef Lipids and HeFH Trials by Baseline eGFR
Blood Pressure and Albuminuria Reduction with Lorundrostat in CKD Stages 1 to 3 in the Launch-HTN Trial
Urine Albumin-to-Creatinine Ratio (UACR) Reduction with the Oral GLP-1 Receptor Agonist Elecoglipron in People with Type 2 Diabetes
Safety of SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among People with CKD and Type 1 Diabetes
National Trends and Guideline Treatment Gaps in SGLT2 Inhibitor Prescribing Among Adults with CKD and Type 2 Diabetes
Pharmacokinetics and Safety of Finerenone in Patients Receiving Peritoneal Dialysis
Polypharmacy and Hyperpolypharmacy in CKD Are Associated More with Cardiometabolic Comorbidity Than with CKD Severity
Treat CKD: An Electronic Health Record (EHR)-Integrated Clinical Decision Support Tool for Risk-Based CKD Care in Primary Care
Modulation of Immune-Mitochondrial Pathways During Acute Exercise in Patients with CKD Using Semaglutide